VolitionRX shares are trading higher after the company announced it is the first to demonstrate the isolation and analysis of greater than 99% pure circulating tumor-derived DNA. The CCO said the company is in active discussions with several liquid biopsy and diagnostic companies to accelerate the development and launch of the technology as soon as possible.